A recent study investigates the effects of tinzaparin and cisplatin on lung cancer cells, providing insights into potential therapeutic strategies. The in vitro findings may contribute to understanding treatment options for lung cancer.

A phase 3 trial shows that treatment-naive patients with stage III–IV nonsmall cell lung cancer receiving early time-of-day immunochemotherapy with sintilimab or pembrolizumab experienced longer progression-free survival. The study involved 210 patients and suggests that timing of treatment may enhance efficacy.

A NIH-led study identifies mobile DNA elements as potential biomarkers for aggressive lung cancer tumors through large-scale, multi-omics analysis. This discovery could pave the way for new diagnostic and therapeutic strategies in lung cancer management.

The Annual Report to the Nation reveals a significant decline in cancer incidence and death rates for the first time since 1998, with notable variations in lung cancer trends across states. This trend is largely attributed to reductions in some of the most prevalent cancer types.